Shares of Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) traded up 3.5% during mid-day trading on Friday . The stock traded as high as $4.20 and last traded at $4.14, with a volume of 77,206 shares. The stock had previously closed at $4.00.

Separately, Zacks Investment Research raised Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 1st.

The company has a 50 day moving average of $3.86 and a 200 day moving average of $4.29. The company’s market capitalization is $54.15 million.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last announced its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.16. The business had revenue of $4.40 million for the quarter, compared to analyst estimates of $3.24 million. Equities research analysts anticipate that Imprimis Pharmaceuticals Inc. will post ($0.94) EPS for the current fiscal year.

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.